Prothena and Roche Reveal New Data for Next-Generation Brain Therapies

At the recent AD/PD™ 2026 conference in Copenhagen, Prothena Corporation and its partners, including Roche, presented significant new findings that offer hope for a more targeted approach to treating the condition. The data focuses on two major fronts: a new "next-generation" antibody designed to clear toxic proteins more effectively, and updated insights from the ongoing Phase 2b PADOVA study of prasinezumab. The most striking development is the introduction of PRX019, an experimental antibody that targets a very specific form of the alpha-synuclein protein. Scientists have long known that the buildup of this protein is a hallmark of the condition, but PRX019 is designed to be more precise than previous efforts. In preclinical studies, it showed a superior ability to bind to and neutralise the "seeds" of these toxic aggregates before they can spread from cell to cell. By stopping this spread, the therapy aims to preserve healthy neurons and potentially slow down the physical decline often seen as the condition progresses. In addition to this new candidate, researchers shared updated analysis from the PADOVA study involving prasinezumab. This trial is specifically looking at people with early-stage symptoms to see if early intervention can make a meaningful difference. The latest data suggests that prasinezumab continues to show a manageable safety profile and remains a leading candidate in the race to find a "disease-modifying" treatment—one that actually changes the course of the condition rather than just masking the symptoms. These presentations underscore a shift in research toward "precision neuroscience." By developing antibodies that can distinguish between harmless proteins and the toxic clusters that cause damage, companies like Prothena are moving closer to therapies that could be tailored to a person's specific biological profile. This progress represents a vital step toward a future where the underlying causes of the condition are not just managed, but actively dismantled.